Troluce Capital Advisors LLC Buys New Position in Stoke Therapeutics, Inc. $STOK

Troluce Capital Advisors LLC bought a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) during the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 652,800 shares of the company’s stock, valued at approximately $21,255,000. Stoke Therapeutics makes up 1.3% of Troluce Capital Advisors LLC’s holdings, making the stock its 19th largest holding.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Kestra Advisory Services LLC acquired a new position in shares of Stoke Therapeutics during the fourth quarter valued at approximately $26,000. KBC Group NV bought a new stake in Stoke Therapeutics during the first quarter worth approximately $36,000. Harbour Investments Inc. lifted its position in Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares during the period. BNP Paribas Financial Markets lifted its position in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares in the last quarter.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $29.30 on Monday. The company’s 50 day simple moving average is $30.41 and its 200 day simple moving average is $32.15. Stoke Therapeutics, Inc. has a 12 month low of $12.25 and a 12 month high of $40.22. The company has a market capitalization of $1.82 billion, a P/E ratio of -10.43 and a beta of 1.17.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. The firm had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. On average, analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the sale, the general counsel directly owned 18,086 shares of the company’s stock, valued at $541,675.70. The trade was a 7.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $30.58, for a total value of $54,891.10. Following the sale, the insider directly owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. This represents a 4.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on STOK shares. BTIG Research reiterated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Monday, May 11th. Weiss Ratings lowered Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, The Goldman Sachs Group initiated coverage on Stoke Therapeutics in a research note on Monday, July 13th. They set a “buy” rating and a $44.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.